Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch.

Transcutaneous immunization (TCI) is an attractive vaccination method compared with conventional injectable vaccines because it is easier to administer without pain. We developed a dissolving microneedle patch (MicroHyala, MH) made of hyaluronic acid and showed that transcutaneous vaccination using MH induced a strong immune response against various antigens in mice. In the present study, we investigated the clinical safety and efficacy of a novel transcutaneous influenza vaccine using MH (flu-MH), which contains trivalent influenza hemagglutinins (15 μg each). Subjects of the TCI group were treated transcutaneously with flu-MH, and were compared with subjects who received subcutaneous injections of a solution containing 15 μg of each influenza antigen (SCI group). No severe local or systemic adverse events were detected in either group and immune responses against A/H1N1 and A/H3N2 strains were induced equally in the TCI and SCI groups. Moreover, the efficacy of the vaccine against the B strain in the TCI group was stronger than that in the SCI group. Influenza vaccination using MH is promising for practical use as an easy and effective method to replace conventional injections systems.

[1]  Youn-Jeong Lee,et al.  New Vaccines Against Influenza Virus , 2022 .

[2]  J. Stockman,et al.  Dissolving polymer microneedle patches for influenza vaccination , 2012 .

[3]  Declan Butler,et al.  Swine flu: One killer virus, three key questions , 2009, Nature.

[4]  M. Prausnitz,et al.  Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge , 2009, Proceedings of the National Academy of Sciences.

[5]  S. Nakagawa,et al.  Transcutaneous vaccines – current and emerging strategies , 2013, Expert opinion on drug delivery.

[6]  P. van Damme,et al.  Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. , 2009, Vaccine.

[7]  S. Nakagawa,et al.  Development and Clinical Study of a Self-Dissolving Microneedle Patch for Transcutaneous Immunization Device , 2013, Pharmaceutical Research.

[8]  Tetsuro Kobayashi,et al.  Langerhans cell antigen capture through tight junctions confers preemptive immunity in experimental staphylococcal scalded skin syndrome. , 2011, The Journal of experimental medicine.

[9]  S. Nakagawa,et al.  Frontiers of transcutaneous vaccination systems: Novel technologies and devices for vaccine delivery , 2013, Vaccine.

[10]  Nicholas S. Kelley,et al.  Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[11]  F. Antunes,et al.  Tuberculosis, a re-emergent disease. , 2005, European journal of radiology.

[12]  Yohei Mukai,et al.  A low-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Yohei Mukai,et al.  Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[14]  M. Albert,et al.  Visualizing the innate and adaptive immune responses underlying allograft rejection by two-photon microscopy , 2011, Nature Medicine.

[15]  G. Glenn,et al.  A recombinant viruslike particle influenza A (H7N9) vaccine. , 2013, The New England journal of medicine.

[16]  R. Webby,et al.  Traditional and New Influenza Vaccines , 2013, Clinical Microbiology Reviews.

[17]  M. Tashiro,et al.  Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine , 2012, Journal of medical virology.